Induction of endogenous γ-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence

Human β-globin disorders are relatively common genetic diseases cause by mutations in the β-globin gene. Increasing the expression of the γ-globin gene has great benefits in reducing complications associated with these diseases. The Oct-1 transcription factor is involved in the transcriptional regulation of the γ-globin gene. The human γ-globin genes (both Aγ and Gγ-globin genes) carry three Oct-1 transcription factor consensus sequences within their promoter regions. We have studied the possibility of inducing γ-globin gene expression using decoy oligonucleotides that target the Oct-1 transcription factor consensus sequence. A double-stranded 22 bp decoy oligonucleotide containing the Oct-1 consensus sequence was synthesized. The results obtained from our in vitro binding assay revealed a strong competitive binding of the decoy oligonucleotide for the Oct-1 transcription factor. When K562 human erythroleukemia cells were treated with the Oct-1 decoy oligonucleotide, significant increases in the level of the γ-globin mRNA were observed. The results of our western blots further demonstrated significant increases of the fetal hemoglobin (HbF, α2γ2) in the Oct-1 decoy oligonucleotide-treated K562 cells. The results of our immunoprecipitation (IP) studies revealed that the treatment of K562 cells with the Oct-1 decoy oligonucleotide significantly reduced the level of the endogenous γ-globin gene promoter region DNA co-precipitated with the Oct-1 transcription factor. These results suggest that the decoy oligonucleotide designed for the Oct-1 transcription factor consensus sequence could induce expression of the endogenous γ-globin gene through competitive binding of the Oct-1 transcription factor, resulting in activation of the γ-globin genes. Therefore, disrupting the bindings of the Oct-1 transcriptional factors with the decoy oligonucleotide provides a novel approach for inducing expression of the γ-globin genes. It also provides an innovative strategy for the treatment of many disease conditions, including sickle cell anemia and β-thalassemia.

[1]  A. Schechter,et al.  Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. , 1995, Blood.

[2]  K. Spurgers,et al.  Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.

[3]  T. Ogihara,et al.  Role of AP-1 complex in angiotensin II-mediated transforming growth factor-beta expression and growth of smooth muscle cells: using decoy approach against AP-1 binding site. , 1998, Biochemical and biophysical research communications.

[4]  M. Mahajan,et al.  Control of beta globin genes , 2007, Journal of cellular biochemistry.

[5]  J. Hensold,et al.  Hemin increases production of β‐like globin RNA transcripts in human erythroleukemia K‐562 cells , 1989 .

[6]  B. Pace,et al.  Pharmacologic Induction of Fetal Hemoglobin Synthesis: Cellular and Molecular Mechanisms , 2001, Pediatric pathology & molecular medicine.

[7]  Y. Cho‐Chung,et al.  CRE-transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: cross-talk with p53 signaling pathway. , 2000, Biochemistry.

[8]  B. Luisi,et al.  The virtuoso of versatility: POU proteins that flex to fit. , 2000, Journal of molecular biology.

[9]  M. Metzger,et al.  Down-regulation of TNF-alpha and VEGF expression by SP1 decoy oligodeoxynucleotides in mouse melanoma tumor , 2003 .

[10]  P. Farnham,et al.  Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. , 2002, Methods.

[11]  R. Gambari,et al.  Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. , 2005, Oncology research.

[12]  J. Hensold,et al.  Hemin increase production of beta-like globin RNA transcripts in human erythroleukemia K-562 cells. , 1989, Developmental genetics.

[13]  S. Surrey,et al.  A single-base change at position -175 in the 5'-flanking region of the G gamma-globin gene from a black with G gamma-beta+ HPFH. , 1988, Blood.

[14]  R. Mantovani,et al.  Sardinian G gamma-HPFH: a T----C substitution in a conserved "octamer" sequence in the G gamma-globin promoter. , 1988, Blood.

[15]  Cameron S. Osborne,et al.  Developmental Regulation of the β-Globin Gene Locus , 2005 .

[16]  Fritz Eckstein,et al.  The versatility of oligonucleotides as potential therapeutics , 2007, Expert opinion on biological therapy.

[17]  H. W. Sharma,et al.  Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. , 1996, Anticancer research.

[18]  N. Tomita,et al.  An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. , 1998, American journal of physiology. Renal physiology.

[19]  P. Glazer,et al.  Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ-globin gene 5' flanking region , 2000 .

[20]  B. Pace,et al.  Understanding mechanisms of γ‐globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[21]  A. Morita,et al.  Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. , 2006, Microbiology and immunology.

[22]  M. Metzger,et al.  Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor , 2003, Gene Therapy.

[23]  Jae-We Cho,et al.  Down-regulation of TGF-beta1-induced type I collagen synthesis by AP-1 transcription factor decoy in scleroderma fibroblasts. , 2006, Journal of dermatological science.

[24]  Masafumi Yamamoto,et al.  Heme Positively Regulates the Expression of β-Globin at the Locus Control Region via the Transcriptional Factor Bach1 in Erythroid Cells* , 2004, Journal of Biological Chemistry.

[25]  R. Eisenman,et al.  Isolation of a thyroid hormone-responsive gene by immunoprecipitation of thyroid hormone receptor-DNA complexes , 1994, Molecular and cellular biology.

[26]  W. Farrar,et al.  The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity. , 2003, Cancer research.

[27]  G. Laurie,et al.  Role of laminin-1, collagen IV, and an autocrine factor(s) in regulated secretion by lacrimal acinar cells. , 1998, American journal of physiology. Cell physiology.

[28]  J. Chiu,et al.  Tissue fibrosis and carcinogenesis: Divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapies , 2006, Journal of cellular biochemistry.

[29]  K. Shirasuna,et al.  Inhibition of epidermal growth factor‐induced invasion by dexamethasone and AP‐1 decoy in human squamous cell carcinoma cell lines , 2002, Journal of cellular physiology.

[30]  Masafumi Yamamoto,et al.  Heme positively regulates the expression of beta-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells. , 2004, The Journal of biological chemistry.

[31]  A. Morita,et al.  Regulation of NF‐κB Signaling by Decoy Oligodeoxynucleotides , 2006 .

[32]  J. Baron,et al.  The Molecular Basis of Blood Diseases , 1994 .

[33]  B. Gilchrest,et al.  A role for interleukin-1 in epidermal differentiation: regulation by expression of functional versus decoy receptors. , 1995, Journal of cell science.

[34]  Gan Wang,et al.  Peptide nucleic acid (PNA) binding-mediated induction of human gamma- globin gene expression , 1999, Nucleic Acids Res..

[35]  Swee Lay Thein,et al.  Molecular therapies in β‐thalassaemia , 2007, British journal of haematology.

[36]  M. Sadelain,et al.  Current status of globin gene therapy for the treatment of β‐thalassaemia , 2008, British journal of haematology.

[37]  Ruiwen Zhang,et al.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? , 2008, Drug discovery today.

[38]  T. Ogihara,et al.  Increase in nuclease resistance and incorporation of NF‐κB decoy oligodeoxynucleotides by modification of the 3′‐terminus , 2007 .

[39]  R. Morishita,et al.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease , 2007, Clinical and Experimental Nephrology.

[40]  T. Kent,et al.  A decoy oligonucleotide inhibiting nuclear factor‐κB binding to the IgGκB consensus site reduces cerebral injury and apoptosis in neonatal hypoxic‐ischemic encephalopathy , 2007, Journal of neuroscience research.

[41]  G. Stamatoyannopoulos.  Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.

[42]  R. Gambari,et al.  Peptide nucleic acid-DNA decoy chimeras targeting NF-kappaB transcription factors: Induction of apoptosis in human primary osteoclasts. , 2004, International journal of molecular medicine.

[43]  Roberto Gambari,et al.  New trends in the development of transcription factor decoy (TFD) pharmacotherapy. , 2004, Current drug targets.

[44]  R. Gambari,et al.  Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression. , 2004, Current drug targets.

[45]  Y. Fei,et al.  An A gamma type of nondeletional hereditary persistence of fetal hemoglobin with a T----C mutation at position -175 to the cap site of the A gamma globin gene. , 1989, Blood.